|
|
| |
| |
|
|
| |
 |
Siam Life Science is a Thailand-based biotechnology company at the forefront of the development of cell technologies and cell processing platforms. Our core strengths are in the establishment of cellular solutions involving primary human liver cell and human liver-derived immortalized cell lines of Asian origin for research, drug development and potentially for the development and commercialization of bio-artificial liver devices.
Cell technologies are becoming increasingly important in human healthcare and drug development processes. Cellular platforms are already widely used in pharmaceutical research and preclinical drug and toxicity testing, most of which involve liver cell based systems. At Siam Life Science, we have identified the current worldwide shortage of human liver cell test systems and the limitations of existing systems as a tremendous business opportunity.
Siam Life Science is a provider of primary liver cells and immortalized liver cell lines to customers worldwide. Its main business activity is to reliably supply sufficient quantities of cellular test systems to meet the global demands for pharmaceutical toxicology testing and pharmacology research. To achieve long-term market leadership, Siam Life Science also invests in and conducts research activities with the goal of deriving hepatocytes from stem cell sources.
At Siam Life Science, our aim is to become a major provider of cell systems and the preferred partner to customers in the life sciences sector.
|
| |
| |
|
 |
Drug metabolism
Human liver tissue and liver-derived hepatocytes and non-cellular systems such as microsomes are already used in pharmacological research. These systems are utilized for preclinical research to gather information about the metabolism of drug candidates before testing them in clinical trials. Information obtained from such research speeds up the identification of leads for development of better and safer drugs. Performing such in-vitro studies with mainly human cell systems are also an important part of existing metabolite toxicity testing strategies. |
| |
|
|
Drug-drug interactions
Many people, particularly the elderly, are required to take a wide variety of medications on a daily basis. Risky combinations of drugs which might cause unwanted side effects and/or toxicity must be avoided. A drug that enhances or inhibits the metabolism of other drugs might reduce its effectiveness or even cause toxicity. Researchers use human liver cell systems to investigate potential drug interactions. The data derived from such studies helps determine whether clinical trials are needed to address drug interactions and also enable doctors to avoid prescribing potentially dangerous combinations of drugs to their patients. |
| |
|
|
Drug toxicity
The liver is a major site of metabolism where drugs and other chemicals are converted into metabolites which are then excreted. However, in some cases, metabolites of drugs may be toxic. The use of human liver cell systems enables investigations of potential metabolite toxicity. With information about drug toxicity, researchers can focus their efforts on those drugs that are likely to be safe. |
| |
|
|
Reducing the use of laboratory animals
Prior to the availability of human liver cells for studies of drug metabolism, drug toxicity and drug-drug interactions, the use of tissue and cells obtained from laboratory animals was unavoidable. With the increasing use of in vitro human cell systems, the need for animals will be dramatically reduced. This will lead to easier compliance with regulatory frameworks intending to reduce animal experimentation in drug development. |
| |
|
|
Advantages of human vs. animal test systems
Studies of drug metabolism, drug toxicity and drug-drug interactions have demonstrated that many drugs are processed and tolerated differently by animals as compared to humans. In many cases the differences are greater than the similarities and results from animal testing are not necessarily representative of what occurs in the human system. Using human cell test systems will eliminate this uncertainty. For this reason, the availability of human cellular test systems will be a major improvement in the safety and predictability of the drug discovery process. |
| |
|
|
|
|
|
|
| |
|
|
